Regenxbio Inc (FRA:RB0)
€ 11.7 0.2 (1.72%) Market Cap: 582.38 Mil Enterprise Value: 351.37 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 65/100

Regenxbio Inc at Chardan Genetic Medicines Conference (Virtual) Transcript

Oct 05, 2021 / 08:00PM GMT
Release Date Price: €27.69 (-18.41%)
Matthew Barcus
Chardan Capital Markets, LLC. - Analyst

Good afternoon. I am Matthew Barcus, a Research Associate here at Chardan. It is my pleasure to introduce our next fireside chat guest. From REGENXBIO, we have Ken Mills, President and CEO. (Operator Instructions). Ken, thank you for joining us today.

Ken Mills
REGENXBIO Inc. - President & CEO

Thanks, Matt, for you and the Chardan team hosting us.

Questions & Answers

Matthew Barcus
Chardan Capital Markets, LLC. - Analyst

Great. Maybe to start things off, would you be able to provide us with an overview of REGENXBIO and the greater mission of the Company?

Ken Mills
REGENXBIO Inc. - President & CEO

Absolutely. REGENXBIO is an AAV gene therapy company focused on a broad pipeline of active clinical trials and an early pipeline of research and development programs. It's been a productive year for us so far this year. We've made really important progress across our clinical pipeline and expect a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot